DOP051 Shorter disease duration is associated with higher response rates to vedolizumab in Crohn’s disease but not ulcerative colitis: a multi-centre consortium analysis
2018
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
2
Citations
NaN
KQI